REGISTERED
on 08 Jun 2021
Last Applicant/ Owned by
201 King of Prussia Road, Suite 501
Radnor
PA
19087
Serial Number
88981530 filed on 12th Dec 2019
Registration Number
6382057 registered on 08th Jun 2021
Correspondent Address
Joshua M. Gerben, Esq.
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
CENTER FOR BREAKTHROUGH MEDICINES
Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting Research Read More
Classification Information
Class [040]
Treatment & Processing of Materials Services
Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting
First Use Date in General
16th Mar 2021
First Use Date in Commerce
16th Mar 2021
Class [042]
Computer & Software Services & Scientific Services
Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research
First Use Date in General
16th Mar 2021
First Use Date in Commerce
16th Mar 2021
Mark Details
Serial Number
No 88981530
Mark Type
No Service Mark
Attorney Docket Number
No 07768-0009
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 08th Jun 2021 | REGISTERED-PRINCIPAL REGISTER |
| 06th May 2021 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 05th May 2021 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 03rd May 2021 | DIVISIONAL PROCESSING COMPLETE |
| 03rd May 2021 | STATEMENT OF USE PROCESSING COMPLETE |
| 26th Apr 2021 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 05th Apr 2021 | USE AMENDMENT FILED |
| 05th Apr 2021 | TEAS STATEMENT OF USE RECEIVED |
| 05th Apr 2021 | DIVISIONAL REQUEST RECEIVED |
| 05th Apr 2021 | TEAS REQUEST TO DIVIDE RECEIVED |